Molecular design and characterization of recombinant long half-life mutants of human tissue factor pathway inhibitor

Thrombosis and Haemostasis

Volumn 93, Issue 6, 2005, Pages 1055-1060

  Bai, Hao ^a   Ma, Duan ^a   Zhang, Yu Gao ^a   Zhang, Nong ^a   Kong, De Sheng ^a   Guo, Hong Shen ^a   Mo, Wei ^a   Tang, Qi Qun ^a   Song, Hou Yan ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Half life; Mutants; Pharmacokinetics; TFPI

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTICOAGULANTS; COMPUTER-AIDED DESIGN; DRUG DESIGN; HALF-LIFE; HUMANS; LDL-RECEPTOR RELATED PROTEINS; LIPOPROTEINS; MALE; MUTAGENESIS; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; THERMODYNAMICS;

EID: 20444450858     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-11-0721     Document Type: Article

References (27)

1. Bajaj MS, Birktoft JJ, Steer SA. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959-72.
2. Park CT, Creasey AA, Wright SD. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood 1997; 89: 4268-74.
3. Warshawsky I, Bu G, Mast A et al. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995; 95: 1773-81.
4. Matyal R, Vin Y, Delude RL. Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock. Intensive Care Med 2001; 27: 1274-80.
5. Opal SM, Palardy JE, Parejo NA et al. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Crit Care Med 2001; 29: 13-7.
6. Abraham E, Reinhart K, Svoboda P et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29: 2081-9.
7. Palmier MO, Hall LJ, Reisch CM et al. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemost 1992; 68: 33-6.
8. Diaz-Collier JA, Palmier MO, Kretzmer KK et al. Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli. Thromb Haemost 1994; 71: 339-46.
9. Yang Yinke, He Xiaofan, Li Juncheng et al. Preparation and characterization of monoclonal antibody against recombinant human tissue factor pathway inhibitor. Chin Med J 1998; 111: 718-21.
10. Holst J, Lindblad B, Westerlund G et al. Pharmacokinetics and delayed experimental anti-thrombotic effect of two domain non-glycosylated tissue factor pathway inhibitor. Thromb Res 1996; 81: 461-70.
11. Kamikubo Y, Hamuro T, Matsuda J et al. The clearance of proteoglycan-associated human recombinant tissue factor pathway inhibitor (h-rTFPI) in rabbits: a complex formation of h- rTFPI with factor Xa promotes a clearance rate of h-rTFPI. Thromb Res 1996; 83:161-73.
12. Abraham E, Reinhart K, Opal S et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290: 238-47.
13. Angus DC, Crowther MA. Unraveling severe sepsis: why did OPTIMIST fail and what's next? JAMA 2003; 290: 256-8.
14. Narita M, Bu G, Olins GM et al. Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem 1995; 270: 24800-4.
15. Warshawsky I, Broze GJ Jr, Schwartz AL. The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci 1994; 91: 6664-8.
16. Warshawsky I, Herz J, Broze GJ Jr et al. The low density lipoprotein receptor-related protein can function independently from heparan sulfate proteoglycans in tissue factor pathway inhibitor endocytosis. J Biol Chem 1996 271: 25873-9.
17. Neels JG, van Den Berg BM, Lookene A et al. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. J Biol Chem 1999; 274: 31305-11.
18. Iakhiaev A, Pendurthi UR, Voigt J et al. Catabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor. J Biol Chem 1999; 274: 36995-7003.
19. Hamik A, Setiadi H, Bu G et al. Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein. J Biol Chem 1999; 274: 4962-9.
20. Higuchi DA, Wun TC, Likert KM et al. The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood 1992; 79: 1712-9.
21. Petersen LC, Bjorn SE, Nordfang O. Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemost 1992; 67: 537-41.
22. Ohkura N, Enjyoji K, Kamikubo Y et al. A novel degradation pathway of tissue factor pathway inhibitor: incorporation into fibrin clot and degradation by thrombin. Blood 1997; 90: 1883-92.
23. Salemink I, Franssen J, Willems GM et al. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity. Thromb Haemost 1998; 80: 273-80.
24. Li A, Wun TC. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity. Thromb Haemost 1998; 80: 423-7.
25. Stalboerger PG, Panetta CJ, Simari RD et al. Plasmin proteolysis of endothelial cell and vessel wall associated tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 923-8.
26. Belaaouaj AA, Li A, Wun TC et al. Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J Biol Chem 2000; 275: 27123-8.
27. Cunningham AC, Hasty KA, Enghild JJ et al. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8. Biochem J 2002; 367: 451-8.